ChemoCentryx, a biopharmaceutical company focused on the treatment of autoimmune diseases, inflammatory disorders and cancer, announced terms for its IPO on Monday. The Mountain View, CA-based company plans to raise $60 million by offering 4 million shares at a price range of $14.00 to $16.00. At the mid-point of the proposed range, ChemoCentryx will command a market value of $555 million. ChemoCentryx, which was founded in 1997 and withdrew a previous IPO filing in 2008, plans to list on the NASDAQ under the symbol CCXI. J.P. Morgan and Citi are the lead underwriters on the deal. This is the fourth biopharmaceutical company to set terms this month.
